Prediction of survival in patients with head and neck cancer using the histoculture drug response assay

Singh, Bhuvanesh; Li, Rongou; Xu, Li; Poluri, Ashok; Patel, Snehal G.; Shaha, Ashok R.; Pfister, David G.; Sherman, Eric J.; Goberdhan, Andy; Hoffman, Robert M.; Shah, Jatin P.

doi:10.1002/hed.10066

Cited by 61 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Histoculture drugresponse assay (HDRA), which cultures three-dimensional tumor tissue highly correlates with histological response to chemotherapy [29]. Furthermore, there are reports which describing that chemosensitivity determined by the HDRA seems to be a strong predictor of survival in patients with malignant tumors [30][31][32][33]. Although there are few reports describing the use of HDRA for bone sarcoma, HDRA would be complementary to evaluation of the chemotherapeutic effects.…”

Section: Discussionmentioning

confidence: 99%

A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma

Miwa

Taki

Yamamoto

et al. 2012

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma

Miwa

Taki

Yamamoto

et al. 2012

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…HDR-Assay ("histoculture drug response assay", HDRA, [22]) erhält durch die Verwendung von Schwamm-Gelen in der Kultur die dreidimensionale Architektur. Schwachpunkte sind der hohe Arbeitsaufwand und die sehr begrenzte Zahl parallel analysierbarer Proben und damit limitierte Zahl prüfbarer Chemotherapeutika und deren Konzentrationen.…”

Section: Der Von Singh Et Al 2002 Publizierteunclassified

“…Schwachpunkte sind der hohe Arbeitsaufwand und die sehr begrenzte Zahl parallel analysierbarer Proben und damit limitierte Zahl prüfbarer Chemotherapeutika und deren Konzentrationen. Er zeigte ein höheres 2-Jahres-Überleben für Patienten mit Chemosensitivität gegenüber Cisplatin (86 vs. 64%; p=0,05), 5-Fluorourazil (85 vs. 64%; p=0,04) und beiden gemeinsam (85 vs. 63%; p=0,01), das auch in multivariater Analyse nach Adjustierung für TNM und Rezidiv signifikant besser war [22]. Der in etwa 7 Tagen durchführba-re Assay würde auch die Differenzierung verschiedener Zelltypen gestatten und hat insofern ein für die prädiktive Testung interessantes Potenzial.…”

Section: Der Von Singh Et Al 2002 Publizierteunclassified

Pharmacological characterization of head and neck cancer in ex-vivo tests

Wichmann

Dietz

2011

HNO

View full text Add to dashboard Cite

Precise knowledge about the chance of success of a given pharmacologic therapy of head and neck squamous cell carcinoma (HNSCC) before starting therapy would be very desirable to guide the selection of the most suitable or the most efficient combination out of the ever-growing spectrum of available pharmaceuticals. This selection has hitherto been made at best on the basis of the availability of guideline-conformant and approved combinations according to results of published clinical studies and approved general effectiveness in HNSCC. However, the inhomogeneous biology of HNSCC depending on localization, varying metastatic behavior, TNM and UICC stage in the context of the patient's general condition and risk status according to lifestyle and occupational exposure make it impossible to accurately predict the success of pharmacological therapy regimens for the individual HNSCC based on today's clinical and pathohistological diagnostics. A solution may lie in the testing of biopsy specimens ex vivo before starting therapy. The present review describes recent advances in ex-vivo tests and discusses the requirements for their inclusion in the decision-making process.

show abstract

“…The three-dimensional tumor histocultures described here has been shown to be a technique that allows tumor tissues to grow in an in vivo-like way with maintenance of tissue histology, function and their sensitivity to drug for a long period of time [13]. Several human tumors such as colorectal, prostate, bladder, gastric, ovarian and breast cancer have been established as histocultures [14].…”

Section: Introductionmentioning

confidence: 99%

Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer

Huang

Lin

et al. 2009

Invest New Drugs

View full text Add to dashboard Cite

In our previous study, a series of novel cyclic cyanoguanidine compounds, eg. 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4- pyrimidinone derivatives have been successfully synthesized and showed remarkable cytotoxicity in several cancer cell lines. In this present study, it is our aim to screen more potential candidates among the cyclic pyridyl cyanoguanidine compounds (BPR-DC-1, 2, 3) by in vitro and in vivo studies for the therapy of lung cancer, alternatively. Our results showed that BPR-DC-2 significantly inhibited proliferation of tumor cells with an IC50 of 3.60 ± 1.27 and 14.81 ± 4.23 μM in human lung carcinoma cells, H69 and A549, respectively by the MTT assay at 48 hr; BPR-DC-2 also obviously suppressed the tumor proliferation and MDR-1 gene expression, even induced cell apoptosis in the ex vivo histocultured lung tumor. We further demonstrated that, in the nude mouse model of metastatic lung cancer, BPR-DC-2 could diminish the tumor mass, retard the progression of metastasis, and prolong the survival time. In addition, it was found that BPR-DC-2 exerted its anti-tumor effects through the inhibition of MDR-1 gene expression and down-regulation of tumor anti-apoptosis signals (activated p-AKT and over-expression of PARP-1) by western blotting analysis. In conclusion, in this present study we have demonstrated that BPR-DC-2, derived from a series of novel synthetic cyclic cyanoguanidine compounds, has proved its potential as an anti-tumor drug candidate in treating lung cancer.

show abstract

Prediction of survival in patients with head and neck cancer using the histoculture drug response assay

Abstract: Chemosensitivity determined by the HDRA seems to be a strong predictor of survival in patients with advanced HNSCC and should be considered further.

Cited by 61 publications

References 16 publications

A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma

A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma

Pharmacological characterization of head and neck cancer in ex-vivo tests

Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer

Contact Info

Product

Resources

About